Cargando…
Human immunodeficiency virus type 1 impairs sumoylation
During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities inclu...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Life Science Alliance LLC
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860096/ https://www.ncbi.nlm.nih.gov/pubmed/35181598 http://dx.doi.org/10.26508/lsa.202101103 |
_version_ | 1784654596198629376 |
---|---|
author | Mete, Bilgül Pekbilir, Emre Bilge, Bilge Nur Georgiadou, Panagiota Çelik, Elif Sutlu, Tolga Tabak, Fehmi Sahin, Umut |
author_facet | Mete, Bilgül Pekbilir, Emre Bilge, Bilge Nur Georgiadou, Panagiota Çelik, Elif Sutlu, Tolga Tabak, Fehmi Sahin, Umut |
author_sort | Mete, Bilgül |
collection | PubMed |
description | During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities including proliferation, stemness, or anti-viral immunity. SUMO peptides oppose pathogen replication and mediate interferon-dependent anti-viral activities. In turn, several viruses and bacteria attack sumoylation to disarm host immune responses. Here, we show that HIV-1 impairs cellular sumoylation and targets the host SUMO E1–activating enzyme. HIV-1 expression in cultured HEK293 cells or in CD4(+) Jurkat T lymphocytes diminishes sumoylation by both SUMO paralogs, SUMO1 and SUMO2/3. HIV-1 causes a sharp and specific decline in UBA2 protein levels, a subunit of the heterodimeric SUMO E1 enzyme, which likely serves to reduce the efficiency of global protein sumoylation. Furthermore, HIV-1–infected individuals display a significant reduction in total leukocyte sumoylation that is uncoupled from HIV-induced cytopenia. Because sumoylation is vital for immune function, T-cell expansion and activity, loss of sumoylation during HIV disease may contribute to immune system deterioration in patients. |
format | Online Article Text |
id | pubmed-8860096 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Life Science Alliance LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-88600962022-03-11 Human immunodeficiency virus type 1 impairs sumoylation Mete, Bilgül Pekbilir, Emre Bilge, Bilge Nur Georgiadou, Panagiota Çelik, Elif Sutlu, Tolga Tabak, Fehmi Sahin, Umut Life Sci Alliance Research Articles During infection, the human immunodeficiency virus type 1 (HIV-1) manipulates host cell mechanisms to its advantage, thereby controlling its replication or latency, and evading immune responses. Sumoylation is an essential post-translational modification that controls vital cellular activities including proliferation, stemness, or anti-viral immunity. SUMO peptides oppose pathogen replication and mediate interferon-dependent anti-viral activities. In turn, several viruses and bacteria attack sumoylation to disarm host immune responses. Here, we show that HIV-1 impairs cellular sumoylation and targets the host SUMO E1–activating enzyme. HIV-1 expression in cultured HEK293 cells or in CD4(+) Jurkat T lymphocytes diminishes sumoylation by both SUMO paralogs, SUMO1 and SUMO2/3. HIV-1 causes a sharp and specific decline in UBA2 protein levels, a subunit of the heterodimeric SUMO E1 enzyme, which likely serves to reduce the efficiency of global protein sumoylation. Furthermore, HIV-1–infected individuals display a significant reduction in total leukocyte sumoylation that is uncoupled from HIV-induced cytopenia. Because sumoylation is vital for immune function, T-cell expansion and activity, loss of sumoylation during HIV disease may contribute to immune system deterioration in patients. Life Science Alliance LLC 2022-02-18 /pmc/articles/PMC8860096/ /pubmed/35181598 http://dx.doi.org/10.26508/lsa.202101103 Text en © 2022 Mete et al. https://creativecommons.org/licenses/by/4.0/This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Research Articles Mete, Bilgül Pekbilir, Emre Bilge, Bilge Nur Georgiadou, Panagiota Çelik, Elif Sutlu, Tolga Tabak, Fehmi Sahin, Umut Human immunodeficiency virus type 1 impairs sumoylation |
title | Human immunodeficiency virus type 1 impairs sumoylation |
title_full | Human immunodeficiency virus type 1 impairs sumoylation |
title_fullStr | Human immunodeficiency virus type 1 impairs sumoylation |
title_full_unstemmed | Human immunodeficiency virus type 1 impairs sumoylation |
title_short | Human immunodeficiency virus type 1 impairs sumoylation |
title_sort | human immunodeficiency virus type 1 impairs sumoylation |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860096/ https://www.ncbi.nlm.nih.gov/pubmed/35181598 http://dx.doi.org/10.26508/lsa.202101103 |
work_keys_str_mv | AT metebilgul humanimmunodeficiencyvirustype1impairssumoylation AT pekbiliremre humanimmunodeficiencyvirustype1impairssumoylation AT bilgebilgenur humanimmunodeficiencyvirustype1impairssumoylation AT georgiadoupanagiota humanimmunodeficiencyvirustype1impairssumoylation AT celikelif humanimmunodeficiencyvirustype1impairssumoylation AT sutlutolga humanimmunodeficiencyvirustype1impairssumoylation AT tabakfehmi humanimmunodeficiencyvirustype1impairssumoylation AT sahinumut humanimmunodeficiencyvirustype1impairssumoylation |